One year in review
One year in review 2018: progress in osteoporosis treatment
A. Figliomeni1, V. Signorini2, M. Mazzantini3
- Rheumatology Unit, Department of Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Pisa, Italy. mmazzant@int.med.unipi.it
CER11599
2018 Vol.36, N°6
PI 0948, PF 0958
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 30526765 [PubMed]
Received: 07/08/2018
Accepted : 09/10/2018
In Press: 06/12/2018
Published: 06/12/2018
Abstract
Osteoporosis is a generalised bone disease characterised by decreased bone mass and deterioration of bone microarchitecture predisposing to fragility fractures. Bone fractures are a remarkable social and economic health problem, and several studies have been carried out in order to reduce their occurrence. Inhibiting bone resorption and increasing bone formation are the mainstay of treatment, anti-catabolic and anabolic, respectively. This review highlights the most recent advances in osteoporosis and reports the evidence of efficacy and safety of anabolic treatment of osteoporosis, as evaluated by randomised, controlled trials published during 2017. As the most common form of secondary osteoporosis, we will also discuss the 2017 state-of-the-art on pathogenesis and treatment of glucocorticoid-induced osteoporosis.
